The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 63 | — | 20.1x | Near average | |
Growth | 17 | — | 5.6% | Below average | |
Quality | 13 | -64.1% | 7.6% | Below average | |
Safety | 63 | 0.0x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Belite Bio, Inc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Belite Bio, Inc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The average price target for Belite Bio stock has shown notable stability with a slight positive bias, as the consensus rose by 0.31% over the past week to reach $204.5. This slight improvement follows a minor decline of 0.24% a month ago, indicating a state of stable reassessment by analysts (count: 2) without any change in coverage weight. The gap between the upper limit ($217) and the lower limit ($187) reflects limited dispersion in expectations, suggesting relative clarity in analysts' vision for the stock's upcoming trajectory.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.